These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7495096)

  • 1. Preliminary in vivo evaluation of a nanofiltered factor IX concentrate.
    Mannucci PM; Tradati F
    Thromb Haemost; 1995 Apr; 73(4):737-8. PubMed ID: 7495096
    [No Abstract]   [Full Text] [Related]  

  • 2. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 4. [A factor IX-concentrate for the treatment of haemophilia B].
    Suomela H; Myllylä G
    Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
    [No Abstract]   [Full Text] [Related]  

  • 5. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needles and needleless devices for infusion of anti-haemophilic factor concentrate: impact on protein structure and function.
    Prabhu S; Kazarian T; Hakobyan N; Jabbar A; Dunham T; Valentino LA
    Haemophilia; 2006 Jan; 12(1):58-61. PubMed ID: 16409176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
    Haanen C; McShine RL; Kunst A
    Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
    [No Abstract]   [Full Text] [Related]  

  • 9. [Preparation of factor IX concentrate with the use of DEAE-cellulose and its therapeutic results].
    Uszyński L; Poszwiński P
    Acta Haematol Pol; 1971; 2(2):109-14. PubMed ID: 5170671
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
    Schulman S; Wallensten R; White B; Smith OP
    Haemophilia; 1999 Mar; 5(2):96-100. PubMed ID: 10215956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine.
    Hrinda ME; Huang C; Tarr GC; Weeks R; Feldman F; Schreiber AB
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):6-14. PubMed ID: 1780768
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune reactive factor IX in acquired factor IX deficiency.
    Lechner K
    Thromb Diath Haemorrh; 1972 Feb; 27(1):19-24. PubMed ID: 5033668
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.